Our genome-wide strategy to identify immunogenic NMD-resistant transcripts has identified five novel cMS mutations (SFRS12IP1, MED8, ASXL1, FBXL3, RGS12) in at least 45% of eleven MSI-High colon cancer cell lines tested. This evidence concerns the gene FBXL3 and malignant colon neoplasm.